177995-39-0

Basic information

• Product Name: 6-BROMOBENZO[D]ISOXAZOL-3-YLAMINE
• Synonyms: 6-broMo-1,2-benzoxazol-3-aMine;3-AMino-6-broMobenzo[d]isoxazole;6-Bromo-1,2-benzisoxazol-3-amine;1,2-Benzisoxazol-3-amine,6-bromo-;6-BROMOBENZO[D]ISOXAZOL-3-AMINE
• CAS NO: 177995-39-0
• Molecular Formula: C₇H₅BrN₂O
• Molecular Weight: 213.03
• Mol File: 177995-39-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 371.101°C at 760 mmHg
• Flash Point: 178.236°C
• Appearance: /
• Density: 1.805g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.716
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.72±0.30(Predicted)
• CAS DataBase Reference: 6-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(177995-39-0)
• EPA Substance Registry System: 6-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(177995-39-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 177995-39-0(Hazardous Substances Data)

Usage

Uses

6-Bromobenzo[D]Isoxazol-3-Amine is a useful research reagent for organic synthesis.

InChI:InChI=1/C7H5BrN2O/c8-4-1-2-5-6(3-4)11-10-7(5)9/h1-3H,(H2,9,10)

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 546-88-3 acetylhydroxamic acid 
• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 

Downstream Products

• 1257211-39-4 (S)-tert-butyl 2-(5-(4-(3-aminobenzo[d]isoxazol-6-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 915301-13-2 (6-bromo-benzo[d]isoxazol-3-yl)-(4-tert-butyl-benzyl)-amine 
• 45744-18-1 hydroxybenzamidine 

Relevant articles and documents

Preparation of 2-hydroxybenzamidines from 3-aminobenzisoxazoles

2-Hydroxybenzamidines have been prepared from 3-aminobenzisoxazoles by reductive cleavage of the nitrogen-oxygen bond using catalytic hydrogenation, Zn/AcOH or NiCl2/NaBH4. This ring-opening reaction can be accomplished chemoselectively in the presence of a variety of hydrogenation-sensitive functional groups including an aryl bromide, benzyl carbamate, and olefin.

Enhanced treatment regimens using mTor inhibitors

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.